NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03
INmune Bio (NASDAQ: INMB) co-founder and CEO Dr. RJ Tesi recently reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston (http://nnw.fm/Wu2Ao). An article discussing the company reads, “‘The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,’ stated Tesi, who is also INmune Bio’s chief medical officer. ‘All of these…







